Tandem Diabetes (TNDM) Tops Q3 EPS by 11c, Revenues Beat; Raises FY19 Revenue Mid-Point Guidance
Tweet Send to a Friend
Tandem Diabetes (NASDAQ: TNDM) reported Q3 EPS of ($0.09), $0.11 better than the analyst estimate of ($0.20). Revenue for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
